Both preclinical and clinical evidence suggests that a poor response to ICIs may be due to a low cancer mutational burden, poor tumor immunogenicity, or the absence of pre-existing tumor-reactive CD8+ T cells [6,7]. The gene discussed is CD8A; the disease is cancer.